111.36
0.94 (0.85%)
| Previous Close | 110.42 |
| Volume | 1,114,998 |
| Price / Earnings (Forward) | 11.45 |
| Price / Sales | 8.26 |
| Price / Book | 88.91 |
| 52 Weeks Range |
| Profit Margin | 44.76% |
| Operating Margin (TTM) | 53.44% |
| Diluted EPS (TTM) | 3.76 |
| Quarterly Revenue Growth (YOY) | 35.20% |
| Quarterly Earnings Growth (YOY) | 53.70% |
| Total Debt/Equity (MRQ) | 318.67% |
| Current Ratio (MRQ) | 8.39 |
| Operating Cash Flow (TTM) | 503.86 M |
| Levered Free Cash Flow (TTM) | 402.43 M |
| Return on Assets (TTM) | 18.50% |
| Return on Equity (TTM) | 147.06% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Halozyme Therapeutics, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | -5.0 |
| Price Volatility | -3.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 0.5 |
| Relative Valuation | 5.0 |
| Financial Health | 5.0 |
| AI Insight | NA |
| Weighted Average | 0.00 |
Select this tab to load the latest available analysis.
|
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 1.11% |
| % Held by Institutions | 101.53% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| DALY JAMES M | 106.94 | - | 1,169 | 125,013 |
| POSARD MATTHEW L. | - | 106.94 | -5,230 | -559,296 |
| TORLEY HELEN | - | 110.12 | -60,000 | -6,607,000 |
| Aggregate Net Quantity | -64,061 | |||
| Aggregate Net Value ($) | -7,041,283 | |||
| Aggregate Avg. Buy ($) | 106.94 | |||
| Aggregate Avg. Sell ($) | 109.32 | |||
| Insider Range ($) | ||||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| TORLEY HELEN | Officer | 08 Oct 2026 | Automatic sell (-) | 20,000 | 109.84 | 2,196,800 |
| TORLEY HELEN | Officer | 08 Oct 2026 | Option execute | 20,000 | - | - |
| TORLEY HELEN | Officer | 07 Oct 2026 | Automatic sell (-) | 20,000 | 110.79 | 2,215,800 |
| TORLEY HELEN | Officer | 07 Oct 2026 | Option execute | 20,000 | - | - |
| TORLEY HELEN | Officer | 06 Oct 2026 | Automatic sell (-) | 20,000 | 109.72 | 2,194,400 |
| TORLEY HELEN | Officer | 06 Oct 2026 | Option execute | 20,000 | - | - |
| POSARD MATTHEW L. | Director | 01 Oct 2026 | Automatic sell (-) | 5,230 | 106.94 | 559,296 |
| DALY JAMES M | Director | 01 Oct 2026 | Acquired (+) | 1,169 | 106.94 | 125,013 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |